There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > DLL4


DLL4 Molecule Information

Name:Delta-like protein 4
Target Synonym:Delta-like protein 4;DLL4;Delta4;Drosophila Delta homolog 4
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase ?

DLL4 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
DL4-H5227 Human Human DLL4 Protein, His Tag
DL4-H5259 Human Human DLL4 Protein, Fc Tag

DLL4 Part of Bioactivity data

Human DLL4, Fc TagHuman DLL4, Fc Tag (Cat. No. DL4-H5259) ELISA bioactivity

Immobilized Human DLL4, Fc Tag (Cat. No. DL4-H5259) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human DLL4 Antibody, Human IgG1 with a linear range of 1-16 ng/mL (QC tested).

Human DLL4, His TagHuman DLL4, His Tag (Cat. No. DL4-H5227) ELISA bioactivity

Immobilized Human DLL4, His Tag (Cat. No. DL4-H5227) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human DLL4 Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).

DLL4 Molecule Synonym Name


DLL4 Molecule Background

Delta-like protein 4 (DLL4) is also known as Drosophila Delta homolog 4 (Delta4), which contains one DSL domain and eight EGF-like domains. DLL4 is expressed in vascular endothelium. DLL4 is involved in the Notch signaling pathway as Notch ligand, which can activates NOTCH1 and NOTCH4. DLL4 is involved in angiogenesis and negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. DLL4 can bind to Notch-1 and Notch-4.

DLL4 References

DLL4 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-cancer stem cell monoclonal antibodies (OncoMed) GITRL-336B22; GITRL-336B3; I/O#2; IO#2; IO#3 Preclinical OncoMed Pharmaceuticals Cancer Details
MEDI-0639 21H3RK; MEDI-0639; Anti-DLL-4-MAb, MEDI0639 Phase Ⅰ MedImmune Small cell lung cancer (SCLC) Details
Demcizumab OMP-21M18; OMP-18M21 Phase Ⅱ OncoMed Pharmaceuticals, GlaxoSmithKline, Celgene Non small cell lung cancer (NSCLC), Solid tumours, Colorectal cancer, Ovarian cancer, Pancreatic cancer Details
TR-009 ABL-001-ABL Bio; ABL001-ABL Bio; NOV-1501 Phase Ⅰ ABL Bio, National OncoVenture, TRIGR Therapeutics Solid tumours Details
Dilpacimab ABT-165; DVD-Ig ABT-165 Phase Ⅱ Abbvie Colorectal cancer Details
Navicixizumab OMP-305B83 Phase Ⅰ OncoMed Pharmaceuticals, Celgene Fallopian tube cancer, Solid tumours, Peritoneum cancer, Ovarian cancer Details
Enoticumab REGN-421; SAR-153192 Phase Ⅰ Regeneron Pharmaceutical, Sanofi Solid tumours Details

This web search service is supported by Google Inc.